Endometrial Cancer Mutations Detected in Uterine Lavage Fluid

The lavage fluid was separated into cellular and acellular fractions by centrifugation. Cellular and cell-free DNA (cfDNA) were isolated from each lavage.

Two targeted next-generation sequencing (NGS) gene panels, one composed of 56 genes and the other of 12 genes, were used for ultra-deep sequencing. To rule out potential NGS-based errors, orthogonal mutation validation was performed using digital polymerase chain reaction (PCR) and Sanger sequencing. In parallel to the genetic study, the hysteroscopy samples were analyzed separately from the advanced genetic workflow using traditional gold-standard classic histopathology methods. DNA sample quantity and integrity were assessed with an ALU repeat qPCR assay (Swift Biosciences, Ann Arbor, MI, USA).

In this prospective study of 107 women, seven were found to have endometrial cancer based upon histopathological evidence and all seven, even those with only microscopic evidence of cancer, had significant cancer-driver gene mutations detected in their uterine lavage fluid, including both the cellular and cell free DNA. Surprisingly, 51 women with no histopathological evidence of cancer also carried cancer-driver mutations in the cells or the cell free DNA from their lavage fluid.

John A. Martignetti, MD, PhD, a professor of Genetics and Genomic Sciences, and a senior author of the study said, “Since a uterine lavage can be easily and quickly performed in a physician's office, our initial idea was that this molecular approach could lead to early detection of pre-cancerous and cancerous conditions of the uterus.” The study was published on December 27, 2016, in the journal Public Library of Science Medicine.

Related Links:
Icahn School of Medicine at Mount Sinai
Swift Biosciences